Aspira Women's Health Inc. announced that Ryan Phan, Ph.D., will join Aspira as Chief Operating and Scientific Officer. Dr. Phan joins Aspira from CareDx where he served as Senior Vice President of Lab Services and Medical Director. Prior to joining CareDx, Dr. Phan was Managing Director and Head of Regional Molecular Genetic Pathology and Cytogenetics at Kaiser Permanente in Northern California, where he led a series of programs related to strategic clinical development, laboratory expansion, and clinical testing.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 USD | -3.76% | -23.81% | -68.63% |
05-15 | Transcript : Aspira Women's Health Inc., Q1 2024 Earnings Call, May 15, 2024 | |
05-15 | Earnings Flash (AWH) ASPIRA WOMEN'S HEALTH Reports Q1 Revenue $2.2M, vs. Street Est of $2.6M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-68.63% | 16.56M | |
-38.51% | 8.15B | |
+8.10% | 3.6B | |
-0.43% | 2.27B | |
-26.02% | 1.9B | |
-17.67% | 1.72B | |
+5.88% | 922M | |
+20.42% | 731M | |
-12.45% | 679M | |
-29.90% | 503M |
- Stock Market
- Equities
- AWH Stock
- News Aspira Women's Health Inc.
- Aspira Women's Health Inc. Appoints Ryan Phan, Ph.D. as Chief Operating and Scientific Officer